Type 3 CNV and anti-VEGF
1 February 2019
| Saruban Pasu
|
Retina / Uvea / Vitreous
The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...
Cataract surgery in patients with Vogt-Koyanagi-Harada
1 February 2019
| Tasmin Berman
|
Retina / Uvea / Vitreous
This retrospective, interventional case series of 286 patients (408 eyes) assessed visual outcome and prognostic factors in patients with Vogt-Koyanagi-Harada (VKH) undergoing cataract surgery between September 2008 and December 2017. Two groups were reviewed. The first group (352 eyes) had...